使用聚 (ADP-ribose) 聚合酶 (PARP) 家族特征和瘤免疫微环境在质瘤中的PARPscore系统
Cheng Zhang1, Juan Feng2, Xia Zhou3
1Department of Neurosurgery, Zigong Third People's Hospital, Zigong, 643020, Sichuan, China.
Discover oncology
|December 26, 2024
概括
蛋白 PAR 聚合酶 (PARP) 的修改影响瘤微环境 (TME) 细胞透. 新的PARPscore揭示了与预后和免疫治疗反应相关的独特模式,为TME复杂性提供了洞察力.
科学领域:
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
- 分子生物学分子生物学
背景情况:
- 免疫反应在瘤进展和治疗中至关重要.
- 蛋白质PAR聚合酶 (PARPs) 修饰在瘤微环境 (TME) 细胞透中的作用尚不清楚.
研究的目的:
- 分析PARP的修饰模式及其与TME细胞透的关联.
- 开发一种指标 (PARPscore) 用于量化瘤中PARP的修饰.
主要方法:
- 利用TCGA和CGGA数据库中的临床和RNA测序数据.
- 使用主要组件分析开发了一个新的PARPscore.
- 分析了PARPs修饰模式,TME透和临床参数之间的相关性.
主要成果:
- 确定了与独特的TME透和免疫类型相关的三个不同的PARP修饰模式.
- 高PARP得分与肌体激活,免疫透减少和生存率降低有关.
- 较低的PARPscore亚型在免疫疗法队列中显示出治疗益处和改善的结果.
结论:
- PARP的修改大大影响了TME.
- 瘤特异性的PARP修饰模式为TME复杂性和免疫治疗反应提供了洞察力.
- 该PARPscore可以预测临床参数和患者预后.
更多相关视频
06:32Evaluation of Biomarkers in Glioma by Immunohistochemistry on Paraffin-Embedded 3D Glioma Neurosphere Cultures
Published on: January 9, 2019
7.8K
09:17Digital Spatial Profiling for Characterization of the Microenvironment in Adult-Type Diffusely Infiltrating Glioma
Published on: September 13, 2022
2.2K
相关概念视频
Tumor Progression
6.3K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.3K
The Tumor Microenvironment
6.3K
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
6.3K
PI3K/mTOR/AKT Signaling Pathway
5.2K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
5.2K
Tumor Immunotherapy
2.6K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.6K
